Regain control through personalized muscle regeneration
Stress urinary incontinence is a highly prevalent and underdiagnosed disorder that affects over 200 million people worldwide. Women are affected twice as often as men, with an estimated 40% of women above the age of 40 suffering from SUI. It has a severe impact on physical and psychological health, and existing treatment options offer only short-lived relief or involve synthetic implants with inherent complications.
During their time at Wyss Zurich, the MUVON team developed a low-risk, minimally invasive treatment against SUI and confirmed safety and feasibility of the tissue therapy in clinical trials. In this treatment, the patient’s own muscle precursor cells (MPC) are isolated, expanded in the lab, and re-injected into the patient’s sphincter muscle. These cells regenerate the damaged tissue and restore function.
